SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report: ~~June~~ 12September 20, 2007 ~~(Date of earliest event reported)~~

(Date of earliest event reported)

XECHEM INTERNATIONAL, INC.

(Exact name of registrant as specified in the charter)

Delaware

(State or other jurisdiction of incorporation)

0-23788

(Commission File No.)

22-3284403

(IRS Employer Identification No.)

~~New~~379 ~~Brunswick Technology Center~~ Thornall

~~100 Jersey Avenue~~Edison, ~~Building B, Suite 310~~ New ~~Brunswick, New~~ Jersey ~~08901-3279 (Address of Principal Executive Offices)~~08818

(~~732) 247-3300~~Address ~~Registrant's~~ of ~~telephone~~Principal ~~number~~Executive ~~including area code~~Offices)

~~NOT APPLICABLE~~ (~~Former name or former address, if changed since last report~~732) 205-0500

Registrant’s telephone number including area code)

NOT APPLICABLE

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

_£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) _£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) _£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) _£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~Page 1 ~~5.02 Departure~~ of ~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.~~3

~~Effective June 12, 2007 Colonel~~Item ~~Bhuwan Pandey, Vice President - International Operations, was relieved of his duties with the Company~~ 8. ~~Colonel~~01 ~~Pandey~~Other ~~has an employment agreement with the Company that calls for payment of six months compensation in such event absent termination for cause. He is the brother of the Company's CEO, Dr. Ramesh Pandey.~~Events

~~SIGNATURE~~Termination of Active Operations with Respect to Xechem India and Other Matters.. Since the departure of Dr. Ramesh Pandey as an employee of the Company, the Company has determined that it is presently deriving no benefit from any continued activities by Xechem India and has ceased any further activities with respect to Xechem (India.) Pvt., Ltd. (“Xechem India”). Dr. Pandey had formed this company together with certain of his relatives in the 1990’s. Dr. Pandey had advised the Company, in 1998, that he had transferred his 2/3 ownership of the outstanding stock of Xechem India to the Company in exchange for reimbursement of organizational expenses associated with Xechem India through such date (estimated at approximately $5,000). Dr. Pandey believed the Company could find dependable supplies of plants and other raw materials in India through informal collaborations and contracts Based on its discussions with Indian sources for such materials, He believed that an Indian corporation would obtain such collaborations and contracts on significantly better terms than would a United States-based corporation.

~~Pursuant~~Since Dr. Pandey’s todeparture from the ~~requirements~~Company, the Company has located a public filing in India stating that 100% of the ~~Securities~~ownership of Xechem India, as of 2005, was held ~~Exchange~~ by ~~Act~~Dr. Pandey and two family members. The Company has searched for documentary evidence of ~~1934~~the transfer and the stock ownership of Xechem India, and has been unable to locate any documentation to that effect.. A representative for Dr. Pandey has advised the ~~registrant~~Company that the ownership of Xechem India is consistent with Dr. Pandey’s prior representation that he transferred 2/3 to the Company, however, Dr. Pandey has ~~duly~~not ~~caused~~produced any further documentation as of this ~~report~~date. The Company continues to besearch ~~signed on~~for ~~its~~stock ~~behalf~~records byof Xechem India that might support the ~~undersigned~~2005 ~~hereunto~~public ~~duly~~filing ~~authorized~~or Dr. Pandey’s representation.

~~Xechem~~Page 2 ~~International,~~of ~~Inc.~~3

~~/s/Ramesh C. Pandey~~SIGNATURE

Pursuant ~~By: Ramesh~~ to C.the ~~Pandey,~~requirements ~~PhD~~of the Securities Exchange Act of 1934, ~~CEO~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 15, 2007

	Xechem International, Inc.




	By:	Robert Swift, Chief Oversight Officer


Dated: September 20, 2007

Page 3 2 of 2 3

Filing Compare · XECHEM INTERNATIONAL INC